| pubmed-article:15157353 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15157353 | lifeskim:mentions | umls-concept:C0220847 | lld:lifeskim |
| pubmed-article:15157353 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15157353 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15157353 | lifeskim:mentions | umls-concept:C0035020 | lld:lifeskim |
| pubmed-article:15157353 | lifeskim:mentions | umls-concept:C0332183 | lld:lifeskim |
| pubmed-article:15157353 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:15157353 | pubmed:dateCreated | 2004-5-25 | lld:pubmed |
| pubmed-article:15157353 | pubmed:abstractText | The response to standard or pegylated interferon (IFN) plus ribavirin (RBV) seems to be lower in hepatitis C virus (HCV)/HIV-coinfected subjects than in HCV-monoinfected patients. Thus, the principles guiding anti-HCV therapy in HIV-negative patients may not apply in the setting of HIV infection. We examined the rate of HCV relapse in 58 HCV/HIV-coinfected subjects who showed undetectable HCV-RNA (<600 IU/ml) at the end of anti-HCV combination therapy. Overall, 19 (32.8%) patients relapsed after discontinuing treatment, a rate significantly higher than that seen in HIV negatives, which is in the range of 15-20%. There were no significant differences between HCV genotypes (33.3% for HCV genotypes 2-3 versus 31.8% for HCV genotypes 1-4) and/or the use of either standard or pegylated IFN (37% versus 29%, respectively). Thus, extended periods of anti-HCV therapy might reduce HCV relapses in HIV-coinfected patients initially responding to therapy. | lld:pubmed |
| pubmed-article:15157353 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15157353 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15157353 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15157353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15157353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15157353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15157353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15157353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15157353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15157353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15157353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15157353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15157353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15157353 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15157353 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:15157353 | pubmed:issn | 0889-2229 | lld:pubmed |
| pubmed-article:15157353 | pubmed:author | pubmed-author:SorianoVincen... | lld:pubmed |
| pubmed-article:15157353 | pubmed:author | pubmed-author:González-Laho... | lld:pubmed |
| pubmed-article:15157353 | pubmed:author | pubmed-author:NúñezMarinaM | lld:pubmed |
| pubmed-article:15157353 | pubmed:author | pubmed-author:Pérez-OlmedaM... | lld:pubmed |
| pubmed-article:15157353 | pubmed:author | pubmed-author:RíosPilarP | lld:pubmed |
| pubmed-article:15157353 | pubmed:author | pubmed-author:García-Samani... | lld:pubmed |
| pubmed-article:15157353 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15157353 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:15157353 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15157353 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15157353 | pubmed:pagination | 351-3 | lld:pubmed |
| pubmed-article:15157353 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:15157353 | pubmed:meshHeading | pubmed-meshheading:15157353... | lld:pubmed |
| pubmed-article:15157353 | pubmed:meshHeading | pubmed-meshheading:15157353... | lld:pubmed |
| pubmed-article:15157353 | pubmed:meshHeading | pubmed-meshheading:15157353... | lld:pubmed |
| pubmed-article:15157353 | pubmed:meshHeading | pubmed-meshheading:15157353... | lld:pubmed |
| pubmed-article:15157353 | pubmed:meshHeading | pubmed-meshheading:15157353... | lld:pubmed |
| pubmed-article:15157353 | pubmed:meshHeading | pubmed-meshheading:15157353... | lld:pubmed |
| pubmed-article:15157353 | pubmed:meshHeading | pubmed-meshheading:15157353... | lld:pubmed |
| pubmed-article:15157353 | pubmed:meshHeading | pubmed-meshheading:15157353... | lld:pubmed |
| pubmed-article:15157353 | pubmed:meshHeading | pubmed-meshheading:15157353... | lld:pubmed |
| pubmed-article:15157353 | pubmed:meshHeading | pubmed-meshheading:15157353... | lld:pubmed |
| pubmed-article:15157353 | pubmed:meshHeading | pubmed-meshheading:15157353... | lld:pubmed |
| pubmed-article:15157353 | pubmed:meshHeading | pubmed-meshheading:15157353... | lld:pubmed |
| pubmed-article:15157353 | pubmed:meshHeading | pubmed-meshheading:15157353... | lld:pubmed |
| pubmed-article:15157353 | pubmed:meshHeading | pubmed-meshheading:15157353... | lld:pubmed |
| pubmed-article:15157353 | pubmed:meshHeading | pubmed-meshheading:15157353... | lld:pubmed |
| pubmed-article:15157353 | pubmed:meshHeading | pubmed-meshheading:15157353... | lld:pubmed |
| pubmed-article:15157353 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15157353 | pubmed:articleTitle | Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients. | lld:pubmed |
| pubmed-article:15157353 | pubmed:affiliation | Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain. vsoriano@dragonet.es | lld:pubmed |
| pubmed-article:15157353 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15157353 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15157353 | lld:pubmed |
